UPDATE: MKM Partners Upgrades Auxilium Pharmaceuticals (AUXL) to Buy
Get Alerts AUXL Hot Sheet
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 10 | New: 42
Join SI Premium – FREE
MKM Partners upgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Neutral to Buy with a price target of $26.00.
Analyst Jon LeCroy said, "Auxilium shares are down 30% since March 4, versus up 2% for the S&P 500, on declines in the company’s Testim testosterone business and after the huge initial ramp for Stendra (erectile dysfunction) slowed in recent months. We note that in the past several weeks, Testim declines appear to have slowed somewhat and Stendra prescriptions continue to grow. We think the recent pullback in Auxilium shares is overdone and we are upgrading shares from Neutral to Buy."
For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.
Shares of Auxilium Pharmaceuticals closed at $22.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades Raia Drogasil SA (RADL3:BZ) to Buy
- Jefferies Double Upgrades Hemnet Group AB (HEM:SS) to Buy
- Inditex (ITX:SM) (IDEXY) PT Raised to EUR51 at HSBC
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, UpgradesRelated Entities
Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!